Study protocol: Safety correction of high dose antipsychotic polypharmacy in Japan

BMC Psychiatry

Volumn 14, Issue 1, 2014, Pages

  Sukegawa, Tsuruhei ^a   Inagaki, Ataru ^b   Yamanouchi, Yoshio ^c   Inada, Toshiya ^d   Yoshio, Takashi ^e   Yoshimura, Reiji ^f   Iwata, Nakao ^g  

^a NATIONAL HOSPITAL ORGANIZATION   (Japan)

^b AOYAMA GAKUIN UNIVERSITY   (Japan)

^c NATIONAL INSTITUTE OF MENTAL HEALTH   (Japan)

^d SEIWA HOSPITAL   (Japan)

^e TOHO UNIVERSITY   (Japan)

^f UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

^g FUJITA HEALTH UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Antipsychotics; High dose; Polypharmacy; Schizophrenia

Indexed keywords

ARIPIPRAZOLE; BLONANSERIN; BROMPERIDOL; CARPIPRAMINE; CHLORPROMAZINE; CLOCAPRAMINE; CLOFEKTON; CLOSPIPRAMINE; EMILACE; EMONAPRIDE; FLUPHENAZINE; HALOPERIDOL; LEVOMEPROMAZINE; LEVOTOMIN; MOPERONE; NEUROLEPTIC AGENT; NOVAMIN; OLANZAPINE; OXYPERTINE; PERICIAZINE; PEROSPIRONE; PERPHENAZINE; PIMOZIDE; PIPAMPERONE; PROCHLORPERAZINE; PROPITAN; PZC; QUETIAPINE; RISPERIDONE; SPIPERONE; SULPIRIDE; SULTOPRIDE; TIMIPERONE; TOLOPELONE; TRIFLUOPERAZINE; UNCLASSIFIED DRUG; ZOTEPINE;

ADULT; ARTICLE; AUTONOMIC DYSFUNCTION; BRIEF ASSESSMENT OF COGNITION IN SCHIZOPHRENIA; CLINICAL EFFECTIVENESS; CLINICAL PROTOCOL; CONTROLLED STUDY; DOSE CALCULATION; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG MEGADOSE; DRUG SAFETY; EURO QOL SCALE; EXTRAPYRAMIDAL SYMPTOM; FOLLOW UP; HOSPITAL PATIENT; HUMAN; JAPAN; MAJOR CLINICAL STUDY; MANCHESTER SCALE; MULTICENTER STUDY; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; OPEN STUDY; OUTCOME ASSESSMENT; OUTPATIENT; POLYPHARMACY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL;

ADULT; ANTIPSYCHOTIC AGENTS; CHLORPROMAZINE; CLINICAL PROTOCOLS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; JAPAN; MALE; MIDDLE AGED; POLYPHARMACY; RESEARCH DESIGN; SCHIZOPHRENIA; TREATMENT OUTCOME;

EID: 84899476915     PISSN: None     EISSN: 1471244X     Source Type: Journal    
DOI: 10.1186/1471-244X-14-103     Document Type: Article

References (19)

1. Correll CU. Antipsychotic polypharmacy, part 1: Shotgun approach or targeted cotreatment. J Clin Psychiatry 2008, 69:674-675. 10.4088/JCP.v69n0422, 18507487.
2. Gallego JA, Bonetti J, Zhang J, Kane JM, Correll CU. Prevalence and correlates of antipsychotic polypharmacy: a systematic review and meta-regression of global and regional trends from the 1970s to 2009. Schizophr Res 2012, 138:18-28. 10.1016/j.schres.2012.03.018, 3382997, 22534420.
3. Sim K, Su A, Leong JY, Yip K, Chong MY, Fujii S, Yang S, Ungvari GS, Si T, Chung EK, Tsang HY, Shinfuku N, Kua EH, Tan CH. High dose antipsychotic use in schizophrenia: findings of the REAP (research on east Asia psychotropic prescriptions) study. Pharmacopsychiatry 2004, 37:175-179. 10.1055/s-2004-827174, 15467975.
4. Weinmann S, Read J, Aderhold V. Influence of antipsychotics on mortality in schizophrenia: systematic review. Schizophr Res 2009, 113:1-11. 10.1016/j.schres.2009.05.018, 19524406.
5. Yoshio T, Inada T, Uno J, Miwa T, Kitagawa K, Miyahara Y, Umeda K, Kato T, Inagaki A, Nabeshima T. Prescription profiles for pharmacological treatment of Japanese inpatients with schizophrenia: comparison between 2007 and 2009. Hum Psychopharmacol 2012, 27:70-75. 10.1002/hup.1272, 22249957.
6. Sukegawa T, Sakamto H, Kanazawa K, Inagaki A, Murasugi K, Yoshizumi A, Oshima I, Tsukada K, Urata J. Aproposal of Reduction and Simplification of Polypharmacy of Antipsychotics. Development of the Treatment and Rehabilitation Guideline for Schizophrenia and the Demonstration Study of its Effectiveness: Final Report of the National Project Team, Supported by the Research Grant for Nervous and Mental Disorders from the Ministry of Health, Labour and Welfare, Japan in 2001 2004, 37-43. Japan: The National Project Team, supported by the research grant for nervous andmental disorders from the Ministry of Health, Labour and Welfare, Urata J, in Japanese with English abstract.
7. Sukegawa T, Ito T, Hasegawa M, Mizuno Y, Inagaki A, Sakamoto H, Kanazawa K, Yoshizumi A, Oshima I, Misawa F, Iwanaga H, Uramura K, Saeki Y, Miyakawa A, Yamauchi Y, Doi K, Hayashi Y, Takata K, Ishizaki K, Amakane H, Morita Y, Hagiwara T, Uchino H, Ashizawa Y, Yabana T, Iwasaki S, Kaigai H, Kishida M, Nagao K, Terai E, et al. A randomized controlled trial on the dose reduction and simplification for polypharmacy of antipsychotics. Tottori J Clin Res 2008, 1:169-181. in Japanese with English abstract.
8. Inagaki A, Inada T. Dose equivalence of psychotropic drugs. Part XXI: dose equivalence of novel antipsychotics: blonanserin. Jap J Clin Psychopharmacol 2008, 5:887-890. (in Japanese).
9. Tanabe A. A study reducing the number of antipsychotic drugs in chronic schizophrenia. Keio Igaku 2000, 77:231-239. (in Japanese with English abstract).
10. Murasugi K, Hagiwara T, Shouda S. Attempt to Correct Antipsychotic Administration to Monotherapy and Dose Reduction for Chronic Schizophrenia Patients. Development of the Treatment and Rehabilitation Guideline for Schizophrenia and the Demonstration Study of its Effectiveness: Final Report of the National Project Team, Supported by the Research Grant for Nervous and Mental Disorders from the Ministry of Health, Labour and Welfare, Japan in 2001 2004, 67-73. Japan: National Project Team, Supported by the Research Grant for Nervous and Mental Disorders from the Ministry of Health, Labour and Welfare, Urata J, in Japanese.
11. Sukegawa T. The table indicating the reduction speed of antipsychotics for reduction and simplification of drug prescriptions. Jap J Clin Psychopharmacol 2011, 14:511-515. (in Japanese with English abstract).
12. Chouinard G, Jones BD. Neuroleptic induced supersensitivity psychosis: clinical and pharmacologic characteristics. Am J Psychiatry 1980, 137:16-21.
13. American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorder, 4th edn.Text Version (DSM-IV-TR) 2000, Washington, DC: American Psychiatric Association, American Psychiatric Association.
14. Takekawa Y, Hori A, Tsunashima K, Ishihara I, Uno M, Murakami K, Nishimura Y, Ino K, Hirai T, Kajimura N, Takayama Y, Hayakawa T. Reliability and validity of Japanese version of Manchester Scale. Seishinigaku 1994, 36:389-394. in Japanese.
15. Inada T DIEPSS A second-generation rating scale for antipsychotic-induced extrapyramidal symptoms: Drug-induced Extrapyramidal Symptoms Scale 2009, Tokyo: Seiwa Shoten Publishers, Inc, in Japanese, DIEPSS.
16. Lingjaerede O, Ahlfors UG, Bech P, Dencker SJ, Elgen K. The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr Scand 1987, 76((suppl334):11--100.
17. Tsuchiya A, Ikeda S, Ikegami N, Nishimura S, Sakai I, Fukuda T, Hamashima C, Hisashige A, Tamura M. Estimating an EQ-5D population value set: the case of Japan. Health Econ 2002, 11:341-353. 10.1002/hec.673, 12007165.
18. Kaneda Y, Sumiyoshi T, Keefe R, Ishimoto Y, Numata S, Ohmori T. Brief assessment of cognition in schizophrenia, validation of the Japanese version. Psychiatry Clin Neurosci 2007, 61:602-609. 10.1111/j.1440-1819.2007.01725.x, 18081619.
19. Song T, Dong Q, Sankoh AJ, Molenberghs G. Evaluation of overall treatment in MMRM. J Biopharm Stat 2013, 23:1281-1293. 10.1080/10543406.2013.834918, 24138432.